Does the media refer more to CLDX or OPK?

In the previous week, Celldex Therapeutics and Celldex Therapeutics both had 1 articles in the media. Celldex Therapeutics' average media sentiment score of 1.31 beat OPKO Health's score of 0.72 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, NVAX or OPK?

Novavax has higher revenue and earnings than OPKO Health. Novavax is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.49 $440.30M -$0.58 N/A OPKO Health $606.90M 1.82 -$225.68M -$0.27 N/A

Is NVAX or OPK more profitable?

Novavax has a net margin of -14.73% compared to OPKO Health's net margin of -36.63%. Novavax's return on equity of -14.82% beat OPKO Health's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% OPKO Health -36.63% -16.78% -10.98%

Does the media favor NVAX or OPK?

In the previous week, Novavax had 7 more articles in the media than OPKO Health. MarketBeat recorded 8 mentions for Novavax and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.72 beat Novavax's score of 0.24 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, INVA or OPK?

Innoviva has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.98 $271.17M $6.01 3.69 OPKO Health $606.90M 1.82 -$225.68M -$0.27 N/A

Is INVA or OPK more profitable?

Innoviva has a net margin of 119.89% compared to OPKO Health's net margin of -36.63%. Innoviva's return on equity of 33.33% beat OPKO Health's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% OPKO Health -36.63% -16.78% -10.98%

Does the media refer more to INVA or OPK?

In the previous week, Innoviva had 8 more articles in the media than OPKO Health. MarketBeat recorded 9 mentions for Innoviva and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.72 beat Innoviva's score of 0.09 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, MNKD or OPK?

MannKind has higher earnings, but lower revenue than OPKO Health. MannKind is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $360.78M 3.01 $5.86M -$0.07 N/A OPKO Health $606.90M 1.82 -$225.68M -$0.27 N/A

Is MNKD or OPK more profitable?

MannKind has a net margin of -6.63% compared to OPKO Health's net margin of -36.63%. MannKind's return on equity of -11.21% beat OPKO Health's return on equity. Company Net Margins Return on Equity Return on Assets MannKind -6.63% -11.21% -3.92% OPKO Health -36.63% -16.78% -10.98%

Does the media refer more to MNKD or OPK?

In the previous week, MannKind had 14 more articles in the media than OPKO Health. MarketBeat recorded 15 mentions for MannKind and 1 mentions for OPKO Health. MannKind's average media sentiment score of 0.81 beat OPKO Health's score of 0.72 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

OPKO Health (OPK) Competitors

$1.46 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.44 -0.02 (-1.37%)

As of 05:45 PM Eastern

Compare

OPK vs. CLDX, BCRX, NVAX, INVA, and MNKD

Should you buy OPKO Health stock or one of its competitors? MarketBeat compares OPKO Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OPKO Health include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.

How does OPKO Health compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Celldex Therapeutics presently has a consensus price target of $49.78, indicating a potential upside of 66.31%. OPKO Health has a consensus price target of $1.55, indicating a potential upside of 6.16%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Celldex Therapeutics is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

Celldex Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

In the previous week, Celldex Therapeutics and Celldex Therapeutics both had 1 articles in the media. Celldex Therapeutics' average media sentiment score of 1.31 beat OPKO Health's score of 0.72 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OPKO Health has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,525.46	-$258.76M	-$4.26	N/A
OPKO Health	$606.90M	1.82	-$225.68M	-$0.27	N/A

64.6% of OPKO Health shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 49.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Celldex Therapeutics has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
OPKO Health	-36.63%	-16.78%	-10.98%

Summary

OPKO Health beats Celldex Therapeutics on 9 of the 15 factors compared between the two stocks.

How does OPKO Health compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals has higher revenue and earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$885.72M	2.44	$263.86M	-$1.78	N/A
OPKO Health	$606.90M	1.82	-$225.68M	-$0.27	N/A

In the previous week, OPKO Health had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 1 mentions for OPKO Health and 0 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.82 beat OPKO Health's score of 0.72 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
BioCryst Pharmaceuticals	Very Positive
OPKO Health	Positive

OPKO Health has a net margin of -36.63% compared to BioCryst Pharmaceuticals' net margin of -51.71%. OPKO Health's return on equity of -16.78% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
OPKO Health	-36.63%	-16.78%	-10.98%

BioCryst Pharmaceuticals presently has a consensus target price of $20.70, suggesting a potential upside of 143.73%. OPKO Health has a consensus target price of $1.55, suggesting a potential upside of 6.16%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe BioCryst Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

Summary

BioCryst Pharmaceuticals beats OPKO Health on 10 of the 17 factors compared between the two stocks.

How does OPKO Health compare to Novavax?

Novavax (NASDAQ:NVAX) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Novavax has higher revenue and earnings than OPKO Health. Novavax is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.49	$440.30M	-$0.58	N/A
OPKO Health	$606.90M	1.82	-$225.68M	-$0.27	N/A

Novavax has a net margin of -14.73% compared to OPKO Health's net margin of -36.63%. Novavax's return on equity of -14.82% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
OPKO Health	-36.63%	-16.78%	-10.98%

53.0% of Novavax shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novavax presently has a consensus target price of $12.13, suggesting a potential upside of 18.99%. OPKO Health has a consensus target price of $1.55, suggesting a potential upside of 6.16%. Given Novavax's higher possible upside, equities research analysts plainly believe Novavax is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

In the previous week, Novavax had 7 more articles in the media than OPKO Health. MarketBeat recorded 8 mentions for Novavax and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.72 beat Novavax's score of 0.24 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, OPKO Health has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Summary

Novavax beats OPKO Health on 9 of the 17 factors compared between the two stocks.

How does OPKO Health compare to Innoviva?

Innoviva (NASDAQ:INVA) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 49.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Innoviva has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.98	$271.17M	$6.01	3.69
OPKO Health	$606.90M	1.82	-$225.68M	-$0.27	N/A

Innoviva has a net margin of 119.89% compared to OPKO Health's net margin of -36.63%. Innoviva's return on equity of 33.33% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
OPKO Health	-36.63%	-16.78%	-10.98%

Innoviva presently has a consensus target price of $36.20, indicating a potential upside of 63.36%. OPKO Health has a consensus target price of $1.55, indicating a potential upside of 6.16%. Given Innoviva's stronger consensus rating and higher probable upside, equities analysts plainly believe Innoviva is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

Innoviva has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

In the previous week, Innoviva had 8 more articles in the media than OPKO Health. MarketBeat recorded 9 mentions for Innoviva and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.72 beat Innoviva's score of 0.09 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats OPKO Health on 12 of the 17 factors compared between the two stocks.

How does OPKO Health compare to MannKind?

MannKind (NASDAQ:MNKD) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

MannKind has a net margin of -6.63% compared to OPKO Health's net margin of -36.63%. MannKind's return on equity of -11.21% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
OPKO Health	-36.63%	-16.78%	-10.98%

49.5% of MannKind shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 49.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MannKind has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, OPKO Health has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

In the previous week, MannKind had 14 more articles in the media than OPKO Health. MarketBeat recorded 15 mentions for MannKind and 1 mentions for OPKO Health. MannKind's average media sentiment score of 0.81 beat OPKO Health's score of 0.72 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind currently has a consensus price target of $8.97, suggesting a potential upside of 154.79%. OPKO Health has a consensus price target of $1.55, suggesting a potential upside of 6.16%. Given MannKind's stronger consensus rating and higher probable upside, equities research analysts clearly believe MannKind is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

MannKind has higher earnings, but lower revenue than OPKO Health. MannKind is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$360.78M	3.01	$5.86M	-$0.07	N/A
OPKO Health	$606.90M	1.82	-$225.68M	-$0.27	N/A

Summary

MannKind beats OPKO Health on 11 of the 17 factors compared between the two stocks.

Get OPKO Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPK vs. The Competition

Export

Metric	OPKO Health	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.10B	$7.17B	$6.44B	$12.46B
Dividend Yield	N/A	1.23%	2.69%	5.22%
P/E Ratio	-5.41	46.43	23.87	24.36
Price / Sales	1.82	78.41	521.52	117.07
Price / Cash	N/A	24.22	41.27	57.13
Price / Book	0.87	7.30	9.99	6.73
Net Income	-$225.68M	$159.22M	$3.56B	$337.03M
7 Day Performance	2.10%	0.73%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	8.55%	4.03%	28.77%	33.98%

OPKO Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPK OPKO Health	1.9476 of 5 stars	$1.46 flat	$1.55 +6.2%	+5.8%	$1.10B	$606.90M	N/A	1,373
CLDX Celldex Therapeutics	2.6382 of 5 stars	$30.14 -4.1%	$49.78 +65.2%	+49.7%	$2.47B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	3.4167 of 5 stars	$8.57 -3.8%	$20.70 +141.5%	-26.3%	$2.26B	$874.84M	N/A	530	Positive News Analyst Forecast
NVAX Novavax	2.0344 of 5 stars	$10.51 -4.2%	$12.13 +15.4%	+40.5%	$1.80B	$1.12B	N/A	1,990
INVA Innoviva	3.3468 of 5 stars	$21.51 +0.4%	$36.20 +68.3%	+5.3%	$1.58B	$411.33M	3.58	100	Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPK) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OPKO Health (OPK) Competitors

OPK vs. CLDX, BCRX, NVAX, INVA, and MNKD

How does OPKO Health compare to Celldex Therapeutics?

Summary

How does OPKO Health compare to BioCryst Pharmaceuticals?

Summary

How does OPKO Health compare to Novavax?

Summary

How does OPKO Health compare to Innoviva?

Summary

How does OPKO Health compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK vs. The Competition

OPKO Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OPKO Health (OPK) Competitors

OPK vs. CLDX, BCRX, NVAX, INVA, and MNKD

How does OPKO Health compare to Celldex Therapeutics?

Do analysts rate CLDX or OPK?

Which has more volatility & risk, CLDX or OPK?

Does the media refer more to CLDX or OPK?

Which has preferable valuation and earnings, CLDX or OPK?

Do institutionals & insiders believe in CLDX or OPK?

Is CLDX or OPK more profitable?

Summary

How does OPKO Health compare to BioCryst Pharmaceuticals?

Which has more volatility & risk, BCRX or OPK?

Do institutionals and insiders believe in BCRX or OPK?

Which has higher valuation and earnings, BCRX or OPK?

Does the media refer more to BCRX or OPK?

Is BCRX or OPK more profitable?

Do analysts prefer BCRX or OPK?

Summary

How does OPKO Health compare to Novavax?

Which has preferable valuation and earnings, NVAX or OPK?

Is NVAX or OPK more profitable?

Do insiders & institutionals believe in NVAX or OPK?

Do analysts rate NVAX or OPK?

Does the media favor NVAX or OPK?

Which has more risk and volatility, NVAX or OPK?

Summary

How does OPKO Health compare to Innoviva?

Do institutionals and insiders have more ownership in INVA or OPK?

Which has better valuation & earnings, INVA or OPK?

Is INVA or OPK more profitable?

Do analysts rate INVA or OPK?

Which has more risk & volatility, INVA or OPK?

Does the media refer more to INVA or OPK?

Summary

How does OPKO Health compare to MannKind?

Is MNKD or OPK more profitable?

Do institutionals and insiders hold more shares of MNKD or OPK?

Which has more risk and volatility, MNKD or OPK?

Does the media refer more to MNKD or OPK?

Do analysts prefer MNKD or OPK?

Which has higher valuation and earnings, MNKD or OPK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK vs. The Competition

OPKO Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools